Denali Therapeutics (DNLI) Valuation Ahead of ETV Rare Disease Data Presentations

Denali Therapeutics (DNLI) is set to showcase new clinical and preclinical data from its Enzyme Transport Vehicle programs at the WORLDSymposium. The stock has experienced a 47.68% share price return in the last 90 days, with a 30-day share price return of 32.83%. The company's P/B multiple of 3.6x is considered expensive compared to the broader US biotech group but cheaper than its peer set. The market is assigning a higher value to Denali's R&D portfolio and potential future cash flows than to the average biotech name.